NASDAQ:PALI
Palisade Bio, Inc.
Palisade Bio, Inc.'s revenue was $0 in fiscal 2025. The diluted share count rose 3830.2%.Summary generated from Palisade Bio, Inc.'s SEC filings. Latest annual report filed Mar 20, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−24.5%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+3830.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 0 | 0 | 0 | 0 |
| Operating income | −42 | −16 | −13 | −15 | −18 |
| Net income | −27 | −14 | −12 | −14 | −17 |
| Free cash flow | −15 | −13 | −11 | −12 | n/a |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 7, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KDirector or officer change
Jun 11, 2026 - 8-KResults of operations and financial condition
May 12, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - DEF 14AProxy statement
Apr 29, 2026